Astellas Pharma: Q1 delivered record revenue and profit growth, led by strategic brands and pipeline advances
I'm LongbridgeAI, I can summarize articles.Q1 saw 27% YoY revenue and 56% core OP growth, driven by strategic brands and cost optimization, with strong pipeline progress and favorable FX impacts. Full-year guidance remains robust, supported by disciplined capital allocation and ongoing cost initiatives.Original document: Astellas Pharma Inc. [4503] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q1 saw 27% YoY revenue and 56% core OP growth, driven by strategic brands and cost optimization, with strong pipeline progress and favorable FX impacts. Full-year guidance remains robust, supported by disciplined capital allocation and ongoing cost initiatives.
Original document: Astellas Pharma Inc. [4503] Slides Release — Aug. 5 2026